AMENDMENTS TO THE SPECIFICATION

Please amend Paragraph [0010] of the specification as follows:

[0010] The AA_1RA used in the pharmaceutical compositions or methods disclosed herein may be a xanthine-derivative compound. The xanthine-derivative compound may be a compound of Formula I or a pharmaceutically acceptable salt thereof,

(I) 

where

each of X_1 and X_2 independently represents oxygen or sulfur;

Q represents:



where Y represents a single bond or alkylene having 1 to 4 carbon atoms, n represents 0 or 1;

each of R_1 and R_2 independently represents hydrogen, lower alkyl, allyl, propargyl, or hydroxy-substituted, oxo-substituted or unsubstituted lower alkyl, and R_3 represents hydrogen or lower alkyl, or

R_4 and R_5 are the same or different and each represent hydrogen or hydroxy, and when both R_4 and R_5 are hydrogen, at least one of R_1 and R_2 is hydroxy-substituted or oxo-substituted lower alkyl,

provided that when Q is



then R_1, R_2 and R_3 are not simultaneously methyl.